ADMP Adamis Pharmaceuticals Corporation

1.31
0  0%
Previous Close 1.31
Open
Price To Book 1.56
Market Cap 62,149,562
Shares 47,442,414
Volume 0
Short Ratio
Av. Daily Volume 334,927

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
Phase 3 development on hold - noted May 9, 2019.
APC-1000
Asthma/COPD
FDA Approval announced September 27, 2018.
Symjepi - low dose
Anaphylaxis
PDUFA date October 31, 2019.
Higher Dose Naloxone Injection
Opioid overdose
Refusal to file letter received February 26, 2019.
APC-8000 (sublingual tadalafil)
Erectile dysfunction

Latest News

  1. Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
  2. Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
  3. Adamis Pharmaceuticals Announces Conditional Acceptance by FDA of Proprietary Name for Higher Dose Naloxone Product
  4. Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT
  5. Adamis Pharmaceuticals (ADMP) Reports Q1 Loss, Misses Revenue Estimates
  6. Adamis: 1Q Earnings Snapshot
  7. Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update
  8. Adamis Pharmaceuticals Schedules First Quarter 2019 Earnings Conference Call and Business Update
  9. Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  10. Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
  11. The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA
  12. Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate
  13. Before You Buy Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), Consider Its Volatility
  14. The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings
  15. Adamis Provides Regulatory Update on Sublingual Tadalafil
  16. Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
  17. Is Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Excessively Paying Its CEO?
  18. The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
  19. Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept